Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease

TM Consultancy: Eisai, BMS, Adaptimmune. Ipsen, Roche, AstraZeneca, MSD, Beigene Funding: MSD (Fig. 1)

Source: Journal of Hepatology - April 20, 2023 Category: Gastroenterology Authors: Tim Meyer, Sevasti Galani, Andre Lopes, Arndt Vogel Tags: Letter to the Editor Source Type: research